The David Hague Early Career Investigator of the Year Award, worth £25,000 in research expenses with a £1,500 personal prize, will be presented each year to the most outstanding early career researcher in the field of biomedical dementia research.
The Award will be judged by an external panel of prominent international researchers, who will be looking for excellence in scientific research, a significant contribution to the field and quality of scientific writing in an essay. Applications are now closed for the 2018 award, and the winner will be announced at the Alzheimer’s Research UK Conference in London, UK on 20/21 March 2018. Applications for the 2019 award will open Spring 2018.
David Edward Hague, 1942–2015
David was born in Stockport, a working class boy with a free spirit; an optimist, funny and curious. He was also blessed with an outstanding brain. The first in his family to go to university, he read biochemistry at Liverpool and hitchhiked to new worlds in the holidays. In 1966 he moved south to St Mary’s Hospital in London to begin his medical research and continue his sporting activities. His doctoral thesis, Some biochemical aspects of thalidomide toxicity, was a significant contribution to understanding how the sedative thalidomide, given to expectant mothers to ease morning sickness, was able to exert its disastrous effects on the unborn child. He subsequently moved to Barts Hospital and trained in medicine. Various clinical and research roles in the UK and US followed, and in 1982, after becoming a full-time single parent, he settled in Finchley as a GP.
David was charming, kind and clever, and mostly lucky. But soon after retirement he developed Alzheimer’s disease. He coped well for several years, knowing that no cure existed but hoping and trusting that one would be found for his grandchildren’s generation. Alzheimer’s ultimately robbed him of his intellect and his independence, and, on 7th September 2015, his life.